Skip to main content
ASTRO 2024 Main banner
Icon Legend
Presentation Icons
Event Add-on
Event Add-on
In Person Only
In Person Only
Off-site Event
Off-site Event
Location: Marriott Marquis
Location: Marriott Marquis
Back

Neil Desai, MD

University of Texas Southwestern Medical Center
Dallas, TX

I am an academic radiation oncologist specializing in genitourinary malignancies at the University of Texas Southwestern in Dallas, Texas. My practice is part of our robust program in HDR/LDR brachytherapy and SAbR for localized prostate cancer and in integrating metastasis directed therapy into various stages of advanced prostate cancer. As an early career investigator, I lead the multi-center randomized control POTEN-C trial (NCT03525262, www.poten-c.org), which is currently interrogating MR-based sparing of neurovascular elements for sexual function preservation, and collaborate on cooperative group studies, including co-leading the in-development NRG GU-010 study concept for genomic risk stratified therapy intensity in unfavorable intermediate risk prostate cancer.


At ASTRO this year, I am honored to discuss the NRG/RTOG 0526 Investigator Teams presentation of updated data from their salvage LDR brachytherapy trial. I look forward to this and other presentations at ASTRO2020 re-invigorating our collaborations and spurring discussions about next steps in our practices, field and research.

Disclosures:

  • Employment: University of Texas Southwesteen:Physician employee:Employee
  • Compensation: Boston Scientific: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Consultant, Research Grants, Research Funding, Research Salary Support, Grant Research Funding, Compensation Payment-End Date: To present ;Telix: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Research Grants, Research Funding, Research Salary Support, Grant Research Funding, Compensation Payment-End Date: 3/2026 ;Society Urologic Nursing (SUNA): Honoraria-End Date: 7/2022 ;Society Urologic Oncology: Honoraria-End Date: 12/2022 ;Asteallas/Pfizer: Research Grants, Research Funding, Research Salary Support,Grant Research Funding-End Date: 9/2027 ;Reflexion: Research Grants, Research Funding, Research Salary Support, Grant Research Funding, Salary Support-End Date: 9/2026
  • Ownership: none
  • Leadership: NCCN:Institutional representative prostate cancer

Presentation(s):